Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Biogen Idec to present latest drug data at ASH 2013

Biogen Idec to present latest drug data at ASH 2013

4th December 2013

Biogen Idec has confirmed that it will be presenting data from its haemophilia clinical development and research programs at the upcoming annual meeting of the American Society of Hematology (ASH).

The company will attend the event in New Orleans from December 7th to 10th 2013, where researchers will discuss ten abstracts covering the breadth of the company's comprehensive basic and clinical research programmes.

New interim phase III data will shed new light on the performance of the haemophilia A therapy Eloctate and the haemophilia B drug Alprolix in paediatric populations.

There will also be a presentations of haemophilia health outcomes research findings, plus results from several non-clinical studies.

Dr Glenn Pierce, senior vice-president of global medical affairs and chief medical officer for Biogen Idec's haemophilia therapeutic area, said: "We are excited to share our findings with physicians on the front lines of haemophilia management to further the understanding of the disorder."

The firm announced new findings from the Eloctate study A-LONG last month, demonstrating its ability to provide effective prevention or reduction of bleeding episodes in haemophilia A patients.ADNFCR-8000103-ID-801668467-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.